CX Institutional’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $781K | Sell |
1,754
-33
| -2% | -$14.7K | 0.03% | 306 |
|
|
2025
Q1 | $866K | Buy |
1,787
+148
| +9% | +$71.7K | 0.03% | 291 |
|
|
2024
Q4 | $660K | Buy |
1,639
+11
| +0.7% | +$4.43K | 0.03% | 306 |
|
|
2024
Q3 | $757K | Buy |
1,628
+3
| +0.2% | +$1.4K | 0.03% | 318 |
|
|
2024
Q2 | $762K | Sell |
1,625
-18
| -1% | -$8.44K | 0.04% | 318 |
|
|
2024
Q1 | $687K | Sell |
1,643
-37
| -2% | -$15.5K | 0.03% | 328 |
|
|
2023
Q4 | $684K | Sell |
1,680
-21
| -1% | -$8.55K | 0.04% | 299 |
|
|
2023
Q3 | $592K | Sell |
1,701
-23
| -1% | -$8K | 0.03% | 313 |
|
|
2023
Q2 | $607K | Buy |
1,724
+3
| +0.2% | +$1.06K | 0.03% | 330 |
|
|
2023
Q1 | $544K | Buy |
1,721
+425
| +33% | +$134K | 0.03% | 342 |
|
|
2022
Q4 | $374K | Buy |
1,296
+95
| +8% | +$27.4K | 0.02% | 403 |
|
|
2022
Q3 | $348K | Buy |
1,201
+480
| +67% | +$139K | 0.02% | 376 |
|
|
2022
Q2 | $204K | Buy |
+721
| New | +$204K | 0.02% | 436 |
|
|
2021
Q4 | – | Sell |
-47
| Closed | -$9K | – | 883 |
|
|
2021
Q3 | $9K | Sell |
47
-287
| -86% | -$55K | ﹤0.01% | 845 |
|
|
2021
Q2 | $67K | Sell |
334
-64
| -16% | -$12.8K | 0.01% | 512 |
|
|
2021
Q1 | $86K | Buy |
398
+86
| +28% | +$18.6K | 0.01% | 401 |
|
|
2020
Q4 | $74K | Buy |
312
+154
| +97% | +$36.5K | 0.01% | 395 |
|
|
2020
Q3 | $43K | Buy |
158
+28
| +22% | +$7.62K | ﹤0.01% | 411 |
|
|
2020
Q2 | $38K | Buy |
130
+22
| +20% | +$6.43K | 0.01% | 362 |
|
|
2020
Q1 | $26K | Buy |
108
+55
| +104% | +$13.2K | ﹤0.01% | 353 |
|
|
2019
Q4 | $12K | Buy |
53
+4
| +8% | +$906 | ﹤0.01% | 416 |
|
|
2019
Q3 | $8K | Buy |
+49
| New | +$8K | ﹤0.01% | 505 |
|
|
2019
Q2 | – | Sell |
-25
| Closed | -$5K | – | 996 |
|
|
2019
Q1 | $5K | Buy |
+25
| New | +$5K | ﹤0.01% | 558 |
|